![]() |
|
|
Vol. 304, Issue 3, 1048-1054, March 2003
Department of Pharmacology and Toxicology, University of Oulu,
Oulu, Finland (J.H.); Astrazeneca R&D Södertälje, Research
DMPK, Södertälje, Sweden (Y.H.); and Division of Molecular
Toxicology, Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden (M.I.-S.)
CYP2E1 is one of the major cytochrome P450 forms whose expression is
strongly inhibited by inflammatory cytokines in humans and rodents. In
the present study, we have used the Fao rat hepatoma cell line that
constitutively expresses CYP2E1 enzyme to investigate mechanisms of
cytokine action. The cells were treated with interleukin (IL)-1
,
tumor necrosis factor-
(TNF
), or IL-6 for 24 or 72 h, and
the expression of CYP2E1 was monitored at the transcriptional, mRNA,
and protein levels. All three cytokines decreased the CYP2E1 mRNA
levels after 24 h, and the effect was even stronger after 72 h. In contrast, significant inhibition of CYP2E1 protein was seen only
after 72 h. In transfection assays using a CYP2E1 5'
3685 to
+29-luciferase construct, it was found that IL-6 inhibited gene
transcription after 24 h, but a similar effect by IL-1
and TNF
was registered only after 72 h. Using 5' deletions of the CYP2E1 5'-reporter construct a responsive region for the IL-6 effect
was located to
669 to
507 base pairs in the
CYP2E1 5'-flanking region. Interestingly, IL-1
, but
not TNF
, was found to reduce hepatocyte nuclear factor
(HNF)-1
binding to the CYP2E1 promotor. However, the
transactivation function of HNF-1
was found to be impaired in Fao
cells. In mouse primary hepatocytes, IL-1
decreased HNF-1
-mediated transactivation. In conclusion, our data indicate that inflammatory cytokines inhibit CYP2E1 expression by multiple mechanisms, including control of HNF-1
function and regulation of
other transcriptional factors acting on the CYP2E1 5'-upstream regulatory region. In addition, regulation of factors of importance for
the CYP2E1 mRNA stability may be involved.
This article has been cited by other articles:
![]() |
K. Nakai, H. Tanaka, K. Hanada, H. Ogata, F. Suzuki, H. Kumada, A. Miyajima, S. Ishida, M. Sunouchi, W. Habano, et al. Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients Drug Metab. Dispos., September 1, 2008; 36(9): 1786 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Arpiainen, F. Raffalli-Mathieu, M. A. Lang, O. Pelkonen, and J. Hakkola Regulation of the Cyp2a5 Gene Involves an Aryl Hydrocarbon Receptor-Dependent Pathway Mol. Pharmacol., April 1, 2005; 67(4): 1325 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
I-N. Park, I. J. Cho, and S. G. Kim Ceramide Negatively Regulates Glutathione S-transferase Gene Transactivation via Repression of Hepatic Nuclear Factor-1 That Is Degraded by the Ubiquitin Proteasome System Mol. Pharmacol., June 1, 2004; 65(6): 1475 - 1484. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kelicen and N. Tindberg Lipopolysaccharide Induces CYP2E1 in Astrocytes through MAP Kinase Kinase-3 and C/EBP{beta} and -{delta} J. Biol. Chem., April 16, 2004; 279(16): 15734 - 15742. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. O. Qiu, M. W. Linder, D. M. Antonino-Green, and R. Valdes Jr. Suppression of Cytochrome P450 2E1 Promoter Activity by Interferon-{gamma} and Loss of Response Due to the -71G>T Nucleotide Polymorphism of the CYP2E1*7B Allele J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 284 - 288. [Abstract] [Full Text] [PDF] |
||||